GlassScriptPhysician profile
Emily Diaz
NPI 1538741731
$2,285.36
in general payments reported to CMS, 2019-2025
31 companies · $99.12 in 2025
The $99.12 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $1,268 · 2023: $84.52 · 2024: $171 · 2025: $99.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $265.55 | 2021-2025 | Advate |
| Grifols USA, LLC | $199.50 | 2021-2022 | |
| Amgen INC. | $164.57 | 2021-2022 | |
| Ucb, INC. | $163.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.21 | 2021-2022 | |
| Abbvie INC. | $154.46 | 2021-2024 | |
| Novo Nordisk INC | $134.20 | 2021-2025 | |
| Lilly USA, LLC | $106.46 | 2021-2022 | |
| Biogen, INC. | $84.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.31 | 2021-2022 | |
| Amarin Pharma, INC. | $72.07 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $64.03 | 2021 | |
| Genentech, INC. | $57.46 | 2023-2025 | Hemlibra |
| Astrazeneca Pharmaceuticals LP | $52.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.90 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $41.45 | 2023 | Hemgenix |
| Vanda Pharmaceuticals INC. | $40.23 | 2022 | |
| Pfizer INC. | $39.80 | 2022-2024 | |
| Janssen Biotech, INC. | $38.67 | 2022 | |
| Genzyme Corporation | $38.02 | 2022-2025 | |
| Glaxosmithkline, LLC. | $37.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.65 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.39 | 2021 | |
| Octapharma USA, INC. | $30.56 | 2024 | Nuwiq |
| Radius Health, INC. | $24.53 | 2022 | |
| Biomarin Pharmaceutical INC. | $21.89 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2021 | |
| Daiichi Sankyo INC. | $15.11 | 2021 | |
| Eisai INC. | $14.25 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.